Clinical Trial Search

Primary: Total Number of Participants With At Least 50% Hair Regrowth — 1 Participants

Primary: Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -6.3; 2.3 score on a scale

Primary: Number of Patients With SALT50 — 1; 1 Participants

Primary: Change in Gene Expression Th2/IL-13, "T22"/IL-22, S100A7 and S100A8, Th1/IFN-gamma, and Th17/IL-17A Jointly Correlated — -0.28 z-score

Primary: Change in SALT Score — 65.8; 24.8; 7.3 score on a scale

Primary: The Proportion of Subjects Achieving at Least a 50% Reduction in Their Scalp Alopecia Areata Severity Scores (SALT Score) From Baseline Values — 8.7; 13.6 percentage of…

Primary: Percent Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -25.6; -30.4; -25.9; -6.3 percent — p=0.011

Primary: Number of Participants With Treatment-Emergent Adverse Events — 0; 3 Participants

Primary: Area Under the Plasma Concentration-Time Profile Over the Dosing Interval of 24 Hours, at Steady State (AUC24ss/AUCtau) of Ritlecitinib on Day 7 — 437.5 Nanogram*hours…

Primary: Clinician's Eyebrow Assessment — 0 score on a scale

Primary: Percent Change in Severity of Alopecia Tool (SALT) Score — 10 percent change

Primary: Likelihood of Depressive Episodes — 1217; 3576 Participants

Primary: Percentage of Participants Achieving at Least a 50% Relative Reduction in Severity of Alopecia Tool (SALT) Score From Baseline at Week 24 — 9.3; 21.4; 47.4; 58.3…

Primary: Percent Change in Severity of Alopecia Tool (SALT) Score — 30.7 Percent change — p=<0.0001

Primary: Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 — 46.4; 18.0 percent change